ACE and diabetic kidney disease: Angiotensin-converting enzyme-inhibitors or angiotensin receptor blockers (ACEI/ARB) are recommended in individuals with prevalent macrovascular complications or diabetic kidney disease (DKD), as is antiplatelet therapy (APT).